Veeva Systems Inc Q1 2023 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Rishi Nitya Jaluria - RBC Capital Markets, Research Division - Analyst : First, I wanted to maybe drill a little bit more into the macro side of things. It looks like things are pretty resilient on your front, which is great to see, but also I think you expected just given the end market you're dealing with. Can you talk a little bit about maybe are there any areas that you are seeing softness at all? I mean we have heard about biotech funding slowing down. Some CROs are slowing down their hiring that they've talked about publicly. And then maybe on the med tech side of the business, any kind of macro things there? Maybe help us understand those pieces. And then I have a follow-up.

Question: Rishi Nitya Jaluria - RBC Capital Markets, Research Division - Analyst : All right. Wonderful. And then, Peter, in your prepared remarks, you talked about some of the success that you're seeing from having the in-person conferences again and arguably how it's maybe more important than before with everyone working remotely. Can you talk to us a little bit about what has just been the general customer feedback off your first in-person conference in, I guess, more than 2 years? And more importantly, as these conferences come back and you start to extend those 2-day conferences, what sort of impact do you expect? Is that something that more customers will start to think strategically about going all-in on Veeva? Is it just from a networking perspective? What sort of kind of benefits do you expect to see now that we're back to in-person conferences for you guys from a business perspective?